{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:52:12Z","timestamp":1775296332258,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["2015\/18\/E\/NZ7\/00509"],"award-info":[{"award-number":["2015\/18\/E\/NZ7\/00509"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jagiellonian University","award":["K\/ZDS\/007128"],"award-info":[{"award-number":["K\/ZDS\/007128"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.eplepsyres.2018.03.024","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T20:26:20Z","timestamp":1522441580000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and \u2013butanamides"],"prefix":"10.1016","volume":"143","author":[{"given":"Anna","family":"Rapacz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"G\u0142uch-Lutwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mordyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Abram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-371X","authenticated-orcid":false,"given":"Krzysztof","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6\u202fHz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2011.05.025","article-title":"Antiepileptic drug therapy: does mechanism of action matter","volume":"21","author":"Brodie","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci Lett."},{"issue":"6","key":"10.1016\/j.eplepsyres.2018.03.024_bib0020","doi-asserted-by":"crossref","first-page":"e0128080","DOI":"10.1371\/journal.pone.0128080","article-title":"Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity","volume":"10","author":"Di Cesare Mannelli","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.tox.2009.06.006","article-title":"Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines","volume":"262","author":"Gasnier","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol. Toxicol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2018.03.024_bib0040","doi-asserted-by":"crossref","first-page":"e0141221","DOI":"10.1371\/journal.pone.0141221","article-title":"Repeated 6-Hz corneal stimulation progressively increases FosB\/(FosB levels in the lateral amygdala and induces seizure generalization to the hippocampus","volume":"10","author":"Giordano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fncel.2016.00281","article-title":"Progressive seizure aggravation in the repeated 6-Hz corneal stimulation model is accompanied by marked increase in hippocampal p-ERK1\/2 immunoreactivity in neurons","volume":"10","author":"Giordano","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2011.10.019","article-title":"Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy","volume":"291","author":"Jaggi","year":"2012","journal-title":"Toxicology"},{"issue":"13","key":"10.1016\/j.eplepsyres.2018.03.024_bib0060","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","article-title":"Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides","volume":"58","author":"Kami\u0144ski","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0065","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.bmc.2016.04.066","article-title":"Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2, 5-dioxopyrrolidin-1-yl)-propanamides and \u2212butanamides","volume":"24","author":"Kami\u0144ski","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.phrs.2016.11.030","article-title":"sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain","volume":"117","author":"Kaufmann","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharep.2014.08.013","article-title":"The antinociceptive effect and mechanisms of action of pregabalin in mice","volume":"67","author":"Kaygisiz","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0080","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nrl.2014.04.012","article-title":"Drug-resistant epilepsy: definition and treatment alternatives","volume":"30","author":"L\u00f3pez Gonz\u00e1lez","year":"2015","journal-title":"Neurologia"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0095","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0105","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-6997(24)01514-X","article-title":"Animal models of nociception","volume":"53","author":"Le Bars","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.03.024_bib0120","first-page":"10","article-title":"Electrographic changes accompanying recurrent seizures under ketogenic diet treatment","volume":"20","author":"Lucchi","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11940-015-0381-2","article-title":"Treatment of neuropathic pain","volume":"17","author":"Mendlik","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2018.03.024_bib0135","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/epi.13764","article-title":"Development and pharmacologic characterization of the rat 6\u202fHz model of partial seizures","volume":"58","author":"Metcalf","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0140","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1734-1140(12)70853-8","article-title":"Pregabalin antinociception and its interaction with tramadol in acute model of pain","volume":"64","author":"Meymandi","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2015.07.017","article-title":"Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2, 5-dioxo-pyrrolidin-1-yl-acetic acid","volume":"102","author":"Obniska","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.pnpbp.2017.07.013","article-title":"HBK-14 and HBK-15, triple 5-HT1A, 5-HT7 and 5-HT3 antagonists with potent antidepressant- and anxiolytic-like properties, increase seizure threshold in various seizure tests in mice","volume":"79","author":"Pytka","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2016.04.033","article-title":"Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2, 5-dioxo-pyrrolidine-1-yl-acetic acid in mice","volume":"781","author":"Rapacz","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0165","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00210-015-1194-2","article-title":"Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2, 5-dione and 3-methylpyrrolidine-2, 5-dione","volume":"389","author":"Rapacz","year":"2016","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0170","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00210-017-1358-3","article-title":"Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy","volume":"390","author":"Rapacz","year":"2017","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0175","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1039\/C6MD00537C","article-title":"Design, synthesis and anticonvulsant-analgesic activity of new N-[(phenoxy)alkyl]- and N-[(phenoxy)ethoxyethyl]aminoalkanols","volume":"8","author":"Rapacz","year":"2017","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2017.12.036","article-title":"Antiallodynic and antihyperalgesic activity of new 3, 3-diphenyl-propionamides with anticonvulsant activity in models of pain in mice","volume":"821","author":"Rapacz","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0190","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1345\/aph.1Q032","article-title":"Pregabalin-induced hepatotoxicity","volume":"45","author":"Sendra","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0195","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.neuropharm.2005.01.013","article-title":"Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats","volume":"48","author":"Shannon","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0200","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s11064-017-2286-9","article-title":"Preclinical comparison of mechanistically different antiseizure, antinociceptive, and\/or antidepressant drugs in a battery of rodent models of nociceptive and neuropathic pain","volume":"42","author":"Smith","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200060050-00005","article-title":"Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy","volume":"60","author":"Tremont-Lukats","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0210","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.tiv.2007.05.014","article-title":"Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells","volume":"21","author":"Westerink","year":"2007","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.eplepsyres.2018.03.024_bib0215","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(99)01307-0","article-title":"Neuropathic pain: aetiology, symptoms, mechanisms, and management","volume":"353","author":"Woolf","year":"1999","journal-title":"Lancet"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118300391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118300391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:38:23Z","timestamp":1760276303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118300391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":43,"alternative-id":["S0920121118300391"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.03.024","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and \u2013butanamides","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}